Handelsbanken Fonder
KLRS

Handelsbanken Fonder’s Kalaris Therapeutics KLRS Stock Holding History

Handelsbanken Fonder’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-583
Closed -$90K – 1705
2022
Q1 		$90K Hold
583
– – ﹤0.01% 1688
2021
Q4 		$173K Hold
583
– – ﹤0.01% 1722
2021
Q3 		$336K Hold
583
– – ﹤0.01% 1559
2021
Q2 		$265K Buy
+583
New +$301K ﹤0.01% 1659

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Handelsbanken Fonder's KLRS Position: Q2 2022 in Review

Handelsbanken Fonder sold out of Kalaris Therapeutics (KLRS) in Q2 2022, closing a stake of 583 shares — an estimated $90K sold.

Handelsbanken Fonder first reported a position in KLRS in Q2 2021 and held it in 4 quarters. The position peaked at $336K in Q3 2021. 84 funds tracked by Wall St. Rank hold KLRS as of Q2 2022.

  • Handelsbanken Fonder reported no remaining Kalaris Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Handelsbanken Fonder sold 583 Kalaris Therapeutics shares in Q2 2022, an estimated $90K.
  • Handelsbanken Fonder first reported a position in Kalaris Therapeutics in Q2 2021 and held it in 4 quarters.
  • Handelsbanken Fonder's Kalaris Therapeutics position peaked at $336K in Q3 2021.
  • 84 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2022.

Based on Handelsbanken Fonder's 13F filing for Q2 2022, filed 3 Aug 2022.